PROMOMED became the general partner of the National Diabetological Congress - 2025

From May 27 to May 30, Moscow hosted the largest scientific and practical event in the field of endocrinology - the X (XXXI) National Diabetological Congress with international participation "Diabetes mellitus – a non-communicable pandemic of the XXI century. Macro- and microvascular complications. Issues of interdisciplinary interaction". PROMOMED Company acted as the General Partner of the congress.


The Congress was timed to coincide with two significant anniversaries: the 100th anniversary of the Russian Association of Endocrinologists and the 100th anniversary of the Endocrinological Research Center. At the solemn plenary session, Peter Alexandrovich Bely, Founder and Chairman of the Board of Directors of PJSC PROMOMED, personally congratulated and thanked Ivan Ivanovich Dedov, President of the Russian Association of Endocrinologists, Scientific Director of the Endocrinological Research Center, Academician of the Russian Academy of Sciences, Hero of Labor of the Russian Federation, chief freelance endocrinologist at the Ministry of Health of the Russian Federation, for cooperation in the fight against diabetes and obesity..

Within the framework of the event, PROMOMED successfully organized three symposiums with the country's leading experts on topical topics, and a bright and interactive stand attracted the attention of over 3,000 participants from Russia and other countries. There was a "Health Cabinet" at the stand, where everyone could assess their metabolic health using bioimpedance and a metabolograph.

PROMMED's active and meaningful participation in the congress confirmed the Company's leadership in developing solutions to combat obesity and diabetes. The company has a wide portfolio of drugs (Reduxin®, Reduxin® Forte, Enligria®, Velgia®, Quintenta®, Tirzetta®), which allows an individual approach to the therapy of each patient in need.